Qilu Pharmaceutical Co., Ltd.: Carcinoma, Non-Small-Cell Lung trials

The registry lists 14 Carcinoma, Non-Small-Cell Lung studies with Qilu Pharmaceutical Co., Ltd. as lead sponsor. 5 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 6Phase 3 4No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• QLS5132 Combination Therapy in Advanced Solid TumorsNot yet recruitingNCT07453394Phase 1/2
• First in Human Study of QLS5316 in Solid TumorsNot yet recruitingNCT07358884Phase 1
• Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With IruplinalkibNot yet recruitingNCT06644495
• To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR MutationRecruitingNCT05555212Phase 1
• A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.RecruitingNCT05487391Phase 3
• Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT07162883Phase 3
• Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsStatus unknownNCT05801107Phase 2
• A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung CancerActive, not recruitingNCT05329025Phase 2
• A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung CancerStatus unknownNCT04641754Phase 2
• Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingNCT04632758Phase 3
• A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor PatientsStatus unknownNCT03389815Phase 1/2
• Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation AbundanceStatus unknownNCT03267654Phase 2
• To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung CancerStatus unknownNCT03195569
• Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung CancerCompletedNCT03169335Phase 3